Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) - Full Text View - ClinicalTrials.gov (2022)

Experimental: Subprotocol A (EGFR activating mutation)

Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drug: Afatinib

Given PO

Other Names:

  • BIBW 2992
  • BIBW2992

Drug: Afatinib Dimaleate

Given PO

Other Names:

  • (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate)
  • BIBW 2992MA2
  • BIBW2992 MA2
  • Gilotrif

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol B (HER2 activating mutation)

Patients with HER2 activating mutation receive afatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drug: Afatinib

Given PO

Other Names:

  • BIBW 2992
  • BIBW2992

Drug: Afatinib Dimaleate

Given PO

Other Names:

  • (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate)
  • BIBW 2992MA2
  • BIBW2992 MA2
  • Gilotrif

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol C1 (MET amplification)

Patients with MET amplification receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drug: Crizotinib

Given PO

Other Names:

  • MET Tyrosine Kinase Inhibitor PF-02341066
  • PF-02341066
  • PF-2341066
  • Xalkori

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol C2 (MET exon 14 deletion/mutation)

Patients with MET exon 14 deletion or other mutations that disrupt exon 14 receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drug: Crizotinib

Given PO

Other Names:

  • MET Tyrosine Kinase Inhibitor PF-02341066
  • PF-02341066
  • PF-2341066
  • Xalkori

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol E (EGFR T790M or rare activating mutation)

Patients with EGFR T790M or rare activating mutation receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Drug: Osimertinib

Given PO

Other Names:

  • AZD-9291
  • AZD9291
  • Mereletinib
  • Tagrisso

Experimental: Subprotocol F (ALK translocation)

Patients with ALK translocation receive crizotinib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drug: Crizotinib

Given PO

Other Names:

  • MET Tyrosine Kinase Inhibitor PF-02341066
  • PF-02341066
  • PF-2341066
  • Xalkori

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol G (ROS1 translocation or inversion)

Patients with ROS1 translocation or inversion receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drug: Crizotinib

Given PO

Other Names:

  • MET Tyrosine Kinase Inhibitor PF-02341066
  • PF-02341066
  • PF-2341066
  • Xalkori

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol H (BRAF V600E/R/K/D mutation)

Patients with BRAF V600E/R/K/D mutation receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Drug: Dabrafenib

Given PO

Other Names:

  • BRAF Inhibitor GSK2118436
  • GSK-2118436
  • GSK-2118436A
  • GSK2118436
Video: Multiple Myeloma

Drug: Dabrafenib Mesylate

Given PO

Other Names:

  • Dabrafenib Methanesulfonate
  • GSK2118436 Methane Sulfonate Salt
  • GSK2118436B
  • Tafinlar

Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Drug: Trametinib

Given PO

Other Names:

  • GSK1120212
  • JTP-74057
  • MEK Inhibitor GSK1120212

Experimental: Subprotocol I (PIK3CA mutation)

Patients with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Drug: Taselisib

Given PO

Other Names:

  • GDC-0032
  • RO5537381

Experimental: Subprotocol J (HER2 amplification >= 7 copy numbers)

Patients with HER2 amplification >= 7 copy numbers receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Biological: Pertuzumab

Given IV

Other Names:

  • 2C4
  • 2C4 Antibody
  • HS627
  • MoAb 2C4
  • Monoclonal Antibody 2C4
  • Omnitarg
  • Perjeta
  • Pertuzumab Biosimilar HS627
  • rhuMAb2C4
  • RO4368451

Biological: Trastuzumab

Given IV

Other Names:

  • ABP 980
  • ALT02
  • Anti-c-ERB-2
  • Anti-c-erbB2 Monoclonal Antibody
  • Anti-ERB-2
  • Anti-erbB-2
  • Anti-erbB2 Monoclonal Antibody
  • Anti-HER2/c-erbB2 Monoclonal Antibody
  • Anti-p185-HER2
  • c-erb-2 Monoclonal Antibody
  • HER2 Monoclonal Antibody
  • Herceptin
  • Herceptin Biosimilar PF-05280014
  • Herceptin Trastuzumab Biosimilar PF-05280014
  • Herzuma
  • Kanjinti
  • MoAb HER2
  • Monoclonal Antibody c-erb-2
  • Monoclonal Antibody HER2
  • Ogivri
  • Ontruzant
  • PF-05280014
  • rhuMAb HER2
  • RO0452317
  • SB3
  • Trastuzumab Biosimilar ABP 980
  • Trastuzumab Biosimilar ALT02
  • trastuzumab biosimilar EG12014
  • Trastuzumab Biosimilar HLX02
  • Trastuzumab Biosimilar PF-05280014
  • Trastuzumab Biosimilar SB3
  • Trastuzumab Biosimilar SIBP-01
  • Trastuzumab-anns
  • Trastuzumab-dkst
  • Trastuzumab-dttb
  • Trastuzumab-pkrb
  • Trastuzumab-qyyp
  • Trazimera

Biological: Trastuzumab Emtansine

Given IV

Other Names:

  • Ado Trastuzumab Emtansine
  • ADO-Trastuzumab Emtansine
  • Kadcyla
  • PRO132365
  • RO5304020
  • T-DM1
  • Trastuzumab-DM1
  • Trastuzumab-MCC-DM1
  • Trastuzumab-MCC-DM1 Antibody-Drug Conjugate
  • Trastuzumab-MCC-DM1 Immunoconjugate

Experimental: Subprotocol K1 (FGFR amplification)

Patients with FGFR amplification receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Drug: Erdafitinib

Given PO

Other Names:

  • Balversa
  • JNJ-42756493

Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol K2 (FGFR mutation or fusion)

Patients with FGFR mutation or fusion receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Drug: Erdafitinib

Given PO


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol L (mTOR mutation)

Patients with mTOR mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Drug: Sapanisertib

Given PO

Other Names:

  • INK-128
  • INK128
  • MLN-0128
  • MLN0128
  • TAK-228

Experimental: Subprotocol M (TSC1 or TSC2 mutation)

Patients with TSC1 or TSC2 mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Drug: Sapanisertib

Given PO

Other Names:

  • INK-128
  • INK128
  • MLN-0128
  • MLN0128
  • TAK-228

Experimental: Subprotocol N (PTEN mutation or deletion and PTEN expression)

Patients with PTEN mutation or deletion and PTEN expression receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis

Video: Getting Clear Answers to Complex Treatment Challlenges in Multiple Myeloma


Drug: PI3K-beta Inhibitor GSK2636771

Given PO

Other Names:

  • GSK-2636771
  • GSK2636771

Experimental: Subprotocol P (PTEN loss)

Patients with PTEN loss receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Drug: PI3K-beta Inhibitor GSK2636771

Given PO

Other Names:

  • GSK-2636771
  • GSK2636771

Experimental: Subprotocol Q (HER2 amplification)

Patients with HER2 amplification receive trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Biological: Trastuzumab

Given IV

Other Names:

  • ABP 980
  • ALT02
  • Anti-c-ERB-2
  • Anti-c-erbB2 Monoclonal Antibody
  • Anti-ERB-2
  • Anti-erbB-2
  • Anti-erbB2 Monoclonal Antibody
  • Anti-HER2/c-erbB2 Monoclonal Antibody
  • Anti-p185-HER2
  • c-erb-2 Monoclonal Antibody
  • HER2 Monoclonal Antibody
  • Herceptin
  • Herceptin Biosimilar PF-05280014
  • Herceptin Trastuzumab Biosimilar PF-05280014
  • Herzuma
  • Kanjinti
  • MoAb HER2
  • Monoclonal Antibody c-erb-2
  • Monoclonal Antibody HER2
  • Ogivri
  • Ontruzant
  • PF-05280014
  • rhuMAb HER2
  • RO0452317
  • SB3
  • Trastuzumab Biosimilar ABP 980
  • Trastuzumab Biosimilar ALT02
  • trastuzumab biosimilar EG12014
  • Trastuzumab Biosimilar HLX02
  • Trastuzumab Biosimilar PF-05280014
  • Trastuzumab Biosimilar SB3
  • Trastuzumab Biosimilar SIBP-01
  • Trastuzumab-anns
  • Trastuzumab-dkst
  • Trastuzumab-dttb
  • Trastuzumab-pkrb
  • Trastuzumab-qyyp
  • Trazimera

Biological: Trastuzumab Emtansine

Given IV

Other Names:

  • Ado Trastuzumab Emtansine
  • ADO-Trastuzumab Emtansine
  • Kadcyla
  • PRO132365
  • RO5304020
  • T-DM1
  • Trastuzumab-DM1
  • Trastuzumab-MCC-DM1
  • Trastuzumab-MCC-DM1 Antibody-Drug Conjugate
  • Trastuzumab-MCC-DM1 Immunoconjugate

Experimental: Subprotocol R (BRAF fusion or BRAF non-V600 mutation)

Patients with BRAF fusion or BRAF non-V600 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Drug: Trametinib

Given PO

Other Names:

  • GSK1120212
  • JTP-74057
  • MEK Inhibitor GSK1120212

Experimental: Subprotocol S1 (NF1 mutation)

Patients with NF1 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Drug: Trametinib

Given PO

Other Names:

  • GSK1120212
  • JTP-74057
  • MEK Inhibitor GSK1120212

Experimental: Subprotocol S2 (GNAQ or GNA11 mutation)

Patients with GNAQ or GNA11 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Drug: Trametinib

Given PO

Other Names:

  • GSK1120212
  • JTP-74057
  • MEK Inhibitor GSK1120212

Experimental: Subprotocol T (SMO or PTCH1 mutation)

Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Drug: Vismodegib

Given PO

Other Names:

  • Erivedge
  • GDC-0449
  • Hedgehog Antagonist GDC-0449

Experimental: Subprotocol U (NF2 inactivating mutation)

Patients with NF2 inactivating mutation receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Drug: Defactinib

Given PO


Drug: Defactinib Hydrochloride

Given PO

Other Names:

  • PF-04554878
  • VS-6063

Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)

Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib malate PO QD for 4 weeks. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis

Video: Breaking Ground: Shaping the Future of Multiple Myeloma Research and Care


Drug: Sunitinib Malate

Given PO

Other Names:

  • SU011248
  • SU11248
  • sunitinib
  • Sutent

Experimental: Subprotocol W (FGFR pathway aberrations)

Patients with FGFR1-3 mutation or translocation receive FGFR Inhibitor AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Drug: FGFR Inhibitor AZD4547

Given PO

Other Names:

  • AZD-4547
  • AZD4547

Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol X (DDR2 S768R, I638F, or L239R mutation)

Patients with DDR2 S768R, I638F, or L239R mutation receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Drug: Dasatinib

Given PO

Other Names:

  • BMS-354825
  • Dasatinib Hydrate
  • Dasatinib Monohydrate
  • Sprycel

Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol Y (Akt mutation)

Patients with Akt mutation receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drug: Capivasertib

Given PO

Other Name: AZD5363


Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61)

Patients with NRAS mutation in codon 12, 13, or 61 receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drug: Binimetinib

Given PO

Other Names:

  • ARRY-162
  • ARRY-438162
  • MEK162
  • Mektovi

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC)

Patients with CCND1, 2, or 3 amplification that have tumor Rb expression by IHC receive palbociclib PO QD for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Drug: Palbociclib

Given PO

Other Names:

  • 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one
  • Ibrance
  • PD 0332991
  • PD 332991
  • PD 991
  • PD-0332991

Experimental: Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein)

Patients with CDK4 or CDK6 amplification and tumor Rb protein receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Drug: Palbociclib

Given PO

Other Names:

  • 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one
  • Ibrance
  • PD 0332991
  • PD 332991
  • PD 991
  • PD-0332991

Experimental: Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC)

Patients with mismatch repair deficiency (loss of MLH1 or MSH2 by IHC) receive nivolumab IV over 30 minutes on days 1 and 15 for 4 cycles and then on day 1 every 28 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Biological: Nivolumab

Given IV

Other Names:

  • BMS-936558
  • CMAB819
  • MDX-1106
  • NIVO
  • Nivolumab Biosimilar CMAB819
  • ONO-4538
  • Opdivo

Experimental: Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)

Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Drug: Larotrectinib

Given PO

Other Names:

  • ARRY 470
  • LOXO 101
  • LOXO-101

Drug: Larotrectinib Sulfate

Given PO

Other Names:

  • ARRY 470 Sulfate
  • LOXO 101 Sulfate
  • LOXO-101 Sulfate
  • Vitrakvi
Video: The role of immune cells and immune checkpoints in multiple myeloma

Experimental: Subprotocol Z1F (PIK3CA mutation)

Patients with PIK3CA mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drug: Copanlisib

Given IV

Other Names:

  • BAY 80-6946
  • PI3K Inhibitor BAY 80-6946

Drug: Copanlisib Hydrochloride

Given IV

Other Names:

  • 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2)
  • Aliqopa
  • BAY 80-6946 Dihydrochloride
  • BAY-80-6946 Dihydrochloride
  • Copanlisib Dihydrochloride

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol Z1G (PTEN loss)

Patients with PTEN loss receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drug: Copanlisib

Given IV

Other Names:

  • BAY 80-6946
  • PI3K Inhibitor BAY 80-6946

Drug: Copanlisib Hydrochloride

Given IV

Other Names:

  • 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2)
  • Aliqopa
  • BAY 80-6946 Dihydrochloride
  • BAY-80-6946 Dihydrochloride
  • Copanlisib Dihydrochloride

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol Z1H (PTEN mutation)

Patients with PTEN mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drug: Copanlisib

Given IV

Other Names:

  • BAY 80-6946
  • PI3K Inhibitor BAY 80-6946

Drug: Copanlisib Hydrochloride

Given IV

Other Names:

  • 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2)
  • Aliqopa
  • BAY 80-6946 Dihydrochloride
  • BAY-80-6946 Dihydrochloride
  • Copanlisib Dihydrochloride

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol Z1I (BRCA1 or BRCA2 gene mutation)

Patients with BRCA1 or BRCA2 gene mutation receive adavosertib PO QD for 5 days for 2 weeks. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Drug: Adavosertib

Given PO

Other Names:

  • AZD-1775
  • AZD1775
  • MK-1775
  • MK1775

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol Z1K (AKT mutation)

Patients receive ipatasertib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Drug: Ipatasertib

Given PO

Other Names:

  • GDC-0068
  • RG-7440

Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Experimental: Subprotocol Z1L (BRAF fusion, aberration or non-V600 mutation)

Patients with a BRAF non-V600 mutation or BRAF fusion, or another BRAF aberration receive ulixertinib (BVD-523FB) PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Drug: Ulixertinib

Give PO

Other Names:

  • BVD-523
  • VRT752271

Experimental: Subprotocol Z1M (LAG-3 expression >= 1%)

Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1.Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Other: Cytology Specimen Collection Procedure

Optional correlative studies

Other Name: Cytologic Sampling


Other: Laboratory Biomarker Analysis

Undergo molecular analysis


Biological: Nivolumab

Given IV

Other Names:

  • BMS-936558
  • CMAB819
  • MDX-1106
  • NIVO
  • Nivolumab Biosimilar CMAB819
  • ONO-4538
  • Opdivo

Biological: Relatlimab

Given IV

Video: Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment

Other Names:

  • BMS-986016
  • BMS986016
  • Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer

Videos

1. Key Research Updates from the 2021 International Myeloma Workshop
(Myeloma Canada)
2. CAR T-cells: an advancement in treating MM?
(VJHemOnc – Video Journal of Hematological Oncology)
3. TRACO: Prostate cancer and CAR-T cells
(NIH VideoCast)
4. EHA 2017: IMWG Conference Series: Making Sense of Treatment
(International Myeloma Foundation)
5. Patient & Family Webinar: From Best of ASH 2021 to 2022 COVID-19 Guidance
(International Myeloma Foundation)

You might also like

Latest Posts

Article information

Author: Ms. Lucile Johns

Last Updated: 05/05/2022

Views: 5267

Rating: 4 / 5 (61 voted)

Reviews: 84% of readers found this page helpful

Author information

Name: Ms. Lucile Johns

Birthday: 1999-11-16

Address: Suite 237 56046 Walsh Coves, West Enid, VT 46557

Phone: +59115435987187

Job: Education Supervisor

Hobby: Genealogy, Stone skipping, Skydiving, Nordic skating, Couponing, Coloring, Gardening

Introduction: My name is Ms. Lucile Johns, I am a successful, friendly, friendly, homely, adventurous, handsome, delightful person who loves writing and wants to share my knowledge and understanding with you.